Epithelioid glioblastoma represents an exceptionally rare and clinically formidable variant of high-grade astrocytic malignancy. First formally characterized in the 2016 World Health Organization classification, this neoplasm poses persistent diagnostic and therapeutic dilemmas for neuro-oncologists, neurosurgeons, and neuropathologists worldwide. Unlike classical glioblastoma, which predominantly affects older adults, this distinct morphological variant routinely arises in significantly younger demographics. Because published literature largely consists of isolated case reports and small cohorts, clinicians frequently encounter diagnostic confusion and therapeutic hesitation. A recent retrospective investigation published in the Journal of Neuro-Oncology systematically evaluated seventeen cases diagnosed over a seven-year interval at a major tertiary care center. The authors delineated critical clinicopathological features, advanced neuroimaging markers, and therapeutic outcomes. Consequently, these findings provide actionable insights that help clinicians accurately differentiate this tumor from metastatic lesions and tailor modern targeted treatment regimens for affected individuals.

Demographic and Anatomical Distribution of Epithelioid Glioblastoma

Understanding the demographic patterns of epithelioid glioblastoma is vital for maintaining appropriate diagnostic suspicion during initial patient presentation. The reported cohort comprised eight females and nine males, demonstrating a relatively balanced gender distribution. Notably, the mean age at diagnosis was 40.88 years, which stands in stark contrast to classical isocitrate dehydrogenase wild-type glioblastoma that typically peaks in the sixth or seventh decade of life. Therefore, clinicians must avoid excluding primary high-grade gliomas when assessing young or middle-aged patients who present with aggressive cerebral lesions.

Anatomically, the majority of tumors developed in supratentorial regions, accounting for nearly sixty-five percent of the analyzed cases. However, clinicians must also remain vigilant regarding atypical central nervous system locations. The investigators documented distinct presentations within deep and midline brain structures, including the basal ganglia, the sellar region, and the pineal gland. Because mass lesions in these atypical regions frequently raise suspicions of germ cell tumors, pituitary adenomas, or craniopharyngiomas, neurosurgeons should integrate rapid intraoperative tissue sampling. Moreover, non-supratentorial localizations underscore the invasive and biologically heterogeneous nature of this high-grade neoplasm.

Advanced Neuroimaging Patterns and Diagnostic Pitfalls

Radiological evaluation remains the cornerstone of initial assessment, yet epithelioid glioblastoma frequently exhibits imaging findings that mimic other intracranial pathologies. On conventional magnetic resonance imaging, the vast majority of cases demonstrate intense, heterogeneous contrast enhancement on T1-weighted sequences alongside variable degrees of internal necrosis. Furthermore, approximately thirty-five percent of lesions exhibit a prominent dural tail sign. This radiological feature commonly leads radiologists and neurosurgeons to misidentify the lesion as an atypical meningioma or a solitary dural metastasis.

To mitigate these critical diagnostic pitfalls, clinical teams must deploy multi-modal imaging protocols early during workup. Advanced functional imaging routinely shows markedly elevated choline-to-creatine and choline-to-N-acetylaspartate ratios, reflecting extreme cellular turnover and neuronal displacement. In addition, arterial spin labeling and dynamic susceptibility contrast perfusion MRI reveal substantial elevations in normalized cerebral blood volume and cerebral blood flow. Diffusion tensor imaging demonstrates prominent distortion and disruption of critical adjacent white matter tracts. Importantly, nearly sixty-five percent of patients present with only mild peritumoral vasogenic edema despite harbor large tumor volumes. Thus, radiologists should not rule out high-grade malignancy simply because profound perilesional edema is absent.

Histopathological Hallmarks and Biomarker Profiles

Histological examination confirms the diagnosis through distinctive cellular architecture and specific immunohistochemical reactivity patterns. Microscopically, the neoplasm consists of sheets of discohesive, rounded epithelioid cells featuring abundant eosinophilic cytoplasm, eccentrically displaced nuclei, and prominent macronucleoli. Multinucleated giant cells and rhabdoid morphological features appear intermittently throughout the tumor bed. Pathologists consistently observe brisk mitotic activity, prominent microvascular proliferation, and extensive geographic necrosis. In the reported cohort, all seventeen cases demonstrated isocitrate dehydrogenase 1 wild-type status alongside markedly elevated Ki-67 proliferation indices.

Immunohistochemical interrogation provides essential diagnostic clarity while eliminating histological mimics such as metastatic melanoma, carcinoma, and malignant rhabdoid tumors. Every evaluated specimen demonstrated retained nuclear expression of integrase interactor 1 (INI-1), which effectively excluded atypical teratoid/rhabdoid tumor. Furthermore, nearly forty-seven percent of cases exhibited focal or diffuse epithelial membrane antigen positivity. Crucially, the investigators identified the BRAF V600E point mutation in over seventy-six percent of cases. This striking mutational frequency separates this variant from classical glioblastoma and provides a direct therapeutic target. Consequently, routine molecular testing for BRAF mutations represents an indispensable standard of care in all suspected cases.

Therapeutic Interventions: Surgical Resection and Beyond

Aggressive multimodal management forms the primary defense against this rapidly progressing malignancy. In the analyzed single-center cohort, all patients underwent gross total surgical resection to achieve maximal cytoreduction and decompress vital neural structures. Following successful surgical intervention, fourteen of the seventeen patients proceeded with adjuvant chemoradiotherapy comprising fractionated external beam radiation and concurrent temozolomide. Nevertheless, epithelioid glioblastoma displays notorious biological virulence that frequently circumvents standard cytotoxic pathways, yielding a modest median overall survival of 12.53 months across the cohort.

Leptomeningeal dissemination represents an alarming clinical complication that significantly worsens individual prognosis. Nearly thirty percent of the study cohort exhibited cerebrospinal fluid seeding and leptomeningeal disease during their disease course. Therefore, clinicians must maintain routine surveillance of the entire craniospinal axis throughout the post-operative monitoring period. When neurological symptoms evolve rapidly or multi-focal spinal deficits emerge, prompt contrast-enhanced neuraxis imaging is mandatory. Timely detection allows for localized palliative radiotherapy or intrathecal treatment strategies before irreversible functional deficits occur.

Targeted Therapies and Emerging Treatment Paradigms

Because conventional chemoradiation achieves limited disease control, precision oncology strategies offer much-needed therapeutic optimism. The high prevalence of the BRAF V600E mutation provides a compelling biological rationale for incorporating small-molecule inhibitors into clinical regimens. In this clinical cohort, patients treated with targeted BRAF inhibition achieved survival durations of 16.93 and 22.67 months. These figures noticeably exceed the historical median survival for this disease entity. Dual inhibition of BRAF and MEK pathways prevents downstream signaling reactivation and provides durable disease stabilization in recurrent or refractory settings.

Additionally, alternating electric fields—known as Tumor Treating Fields—represent an attractive non-invasive therapeutic modality for high-grade gliomas. In the reviewed study, two patients received adjuvant Tumor Treating Fields alongside standard medical care, surviving for 12.53 and 16.63 months, respectively. This biophysical approach disrupts mitotic spindle assembly and halts tumor cell division without exacerbating systemic pharmacological toxicity. Consequently, combining gross total resection, adjuvant chemoradiation, Tumor Treating Fields, and molecularly guided kinase inhibition appears to provide the most favorable survival trajectory. Multidisciplinary teams must actively collaborate to implement these novel paradigms early in the treatment algorithm.

Frequently Asked Questions

How does epithelioid glioblastoma differ from conventional glioblastoma?

Epithelioid glioblastoma typically presents at a younger median age, around forty years, compared to conventional glioblastoma. Histologically, it exhibits discohesive epithelioid cells, frequent rhabdoid features, and high rates of BRAF V600E alterations. Furthermore, this variant displays a distinct propensity for early leptomeningeal dissemination and carries a shorter overall survival.

Why is molecular testing for the BRAF V600E mutation essential in this condition?

Molecular testing for BRAF V600E is essential because more than seventy percent of these tumors harbor this specific actionable alteration. Identifying this mutation confirms diagnostic classification and immediately unlocks targeted therapy opportunities using oral BRAF and MEK inhibitors, which significantly prolong survival in patients with progressive or recurrent disease.

What role do Tumor Treating Fields play in managing this variant?

Tumor Treating Fields utilize low-intensity, intermediate-frequency alternating electric fields to disrupt mitotic protein structures in dividing malignant cells. When integrated into standard adjuvant therapy protocols, this regional modality enhances local tumor control, delays disease progression, and prolongs overall survival without adding substantial systemic pharmacological toxicity for patients.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide medical advice, diagnosis, or treatment. Medical professionals should always use their clinical judgment and conduct their own research before making clinical decisions. Refer to the latest local and national guidelines for clinical practice.

References

Yi GZ et al. Clinical, pathological, radiological features and prognosis of epithelioid glioblastoma: a retrospective single center study. J Neurooncol. 2025 Aug. doi: 10.1007/s11060-025-05046-5. PMID: 40266499.

Kleinschmidt-DeMasters BK et al. Epithelioid glioblastoma: a comprehensive review of clinical, pathological, and molecular aspects. Brain Pathol. 2017;27(6):830-842.

Schreck KC et al. BRAF V600E-mutant high-grade glioma: clinical characteristics, targeted therapies, and future directions. Neurooncol Adv. 2022;4(1):vdac078.